Please login to the form below

Not currently logged in
Email:
Password:

Zurampic

This page shows the latest Zurampic news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.

Latest news

  • Ironwood claims FDA OK for former AZ gout drug Ironwood claims FDA OK for former AZ gout drug

    Ironwood bought rights to Duzallo (allopurinol and lesinurad) and single-agent Zurampic (lesinurad) from AstraZeneca last year in a $265m deal, including $100m upfront, which came amid a massive slimming down ... The approval of Duzallo was based on the

  • Grünenthal buys Zomig rights as AZ slimming drive continues Grünenthal buys Zomig rights as AZ slimming drive continues

    AstraZeneca has sold a raft of older or non-core products over the past two years, including a $230m deal with Grünenthal for gout drug Zurampic.

  • AstraZeneca sells rights to seven anaesthetics in $770m deal AstraZeneca sells rights to seven anaesthetics in $770m deal

    AZ transferred EU and Latin America rights for its recently approved gout drug Zurampic to Gruenenthal in a deal valued at £230m, and sold its late-stage psoriasis candidate brodalumab to

  • AZ sells Zurampic rights to Gruenenthal for $230m AZ sells Zurampic rights to Gruenenthal for $230m

    AstraZeneca (AZ) has continued to refine its portfolio with the sale of European and Latin American rights to gout drug Zurampic. ... AZ previously sold US rights to Zurampic and the follow-up to Ironwood Pharmaceuticals for $265m plus royalties.

  • AZ adds gout drug Zurampic to asset sale AZ adds gout drug Zurampic to asset sale

    AZ adds gout drug Zurampic to asset sale. Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product. ... Gout therapy Zurampic is the latest product to be sold off by AstraZeneca in a drive to focus its energies on core

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both

  • Deal Watch June 2016 Deal Watch June 2016

    As part of the transaction Grünenthal has the option to take over manufacturing of Zurampic from AstraZeneca from October 2021. ... licence. 270. AstraZeneca/ Grünenthal. Zurampic (lesinurad) and lesinurad fixed-dose combo with allopurinol for

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... Annual US sales of Zurampic are estimated by Ironwood at

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics